Use of 5HT6 antagonists

US6380199B1 · kind B1 · utility

Assignee

• SmithKline Beechman, p.l.c. · GB

Inventors

• Charles Alan Reavill · Stevenage, GB
• Carol Routledge · London, GB

Key dates

• Filing date: Apr 17, 2001
• Grant date: Apr 30, 2002
• Expiry date: Apr 17, 2021

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating ADHD comprising administering a 5-HT6 receptor antagonist according to formula (A) hereinbelow: wherein:P is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur;A is a single bond, a C1-6alkylene or a C1-6alkenylene group;R1 is halogen, C1-6alkyl optionally substituted by one or more halogen atoms, C3-6cycloalkyl, C1-6alkoxy, OCF3, hydroxy, hydroxyC1-6alkyl, hydroxyC1-6alkoxy, C1-6alkoxyC1-6alkoxy, C1-6alkanoyl, nitro, amino, C1-6alkylamino or diC1-6alkylamino, cyano or R1 is phenyl, naphthyl, a bicyclic heterocyclic ring or is a 5 to 7-membered heterocyclic ring each containing 1 to 4 heteroatoms selected from oxygen, nitrogen or sulphur;n is 0, 1, 2, 3, 4, 5 or 6,R2 is hydrogen, C1-6 alkyl or aryl C1-6 alkyl;R3 is a group R5 or together with R5 forms a group (CH2)2O or (CH2)3O or R3 is linked to R2 to form a group (CH2)2 or (CH2)3;R4 is —X(CH2)p—R6 where X is a single bond, CH2, O, NH or N—C1-6 alkyl and p is 0 to 6 and R6 is an optionally substituted 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from …